A mRNA universal flu vaccine is in early stages of development
![](/46/pdcnewsitem/11/94/90/784x590%20news%20header%20(20).png)
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA.
A universal flu vaccine has long been considered the El Dorado of vaccines, and with the recent COVID-19 pandemic giving rise to the expedited development of numerous vaccines, this has never seemed more within reach.
Claudia Arevalo from the University of Pennsylvania, PA, USA, and colleagues have produced a mRNA lipid nanoparticle vaccine, which could be used as the basis for such a universal vaccine. The vaccine contains antigens from 20 subtypes of influenza A and B viruses, in other words, all known strains of the virus.
When tested in animals the vaccine triggered the production of cross-reactive and subtype-specific antibodies and protected against symptoms and death after infection. This result was seen after infection with strains of the virus with both matched and mismatched antigens.
Previous attempts at a universal vaccine have contained antigens for each particular subtype, but with Arevalo’s vaccine a smaller number of antigens are used, which are specific to multiple strains, therefore still protecting against all known forms of the viruses.
During the COVID-19 pandemic, Pfizer and BioNTech and Moderna made breakthroughs in using mRNA to develop effective vaccines against SARS-CoV-2. This step forward in technology, proven to be safe and effective, has led to increased research into the use of mRNA.
Arevalo’s team decided to build on this success and combine it with nanotechnology to develop 20 different mRNAs encapsulated in nanoparticles. Each particle encoded for a different hemagglutinin antigen, which helps the virus enter cells.
In mice, antibody levels remained stable for up to 4 months post vaccination. The results, published in Science, were more promising than shown by previous types of multivalent vaccines.
Questions regarding the probability of a vaccine that contains antibodies to virus strains that have not yet been seen in circulation in humans obtaining approval are valid, spurring further discussions surrounding how we approach protecting against viruses of pandemic potential in the future.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance